Tepoxalin

Basic Information

Item Value
DrugBank ID DB11466
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 36

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 osteoarthritis KG + DL
2 osteoarthritis susceptibility KG + DL
3 rheumatoid arthritis KG + DL
4 gout KG + DL
5 hemoglobinopathy KG + DL
6 pseudoachondroplasia KG + DL
7 brachyolmia KG + DL
8 acromesomelic dysplasia, Hunter-Thompson type KG + DL
9 beta-thalassemia with other manifestations KG + DL
10 partial deletion of the short arm of chromosome 16 KG + DL
11 myosclerosis KG + DL
12 colobomatous microphthalmia-rhizomelic dysplasia syndrome KG + DL
13 brachyolmia-amelogenesis imperfecta syndrome KG + DL
14 pyruvate kinase deficiency of red cells KG + DL
15 hemolytic anemia due to glucophosphate isomerase deficiency KG + DL
16 pyropoikilocytosis, hereditary KG + DL
17 arthropathy KG + DL
18 brachydactyly-syndactyly syndrome KG + DL
19 myocardial infarction KG + DL
20 female breast carcinoma KG + DL
21 congestive heart failure KG + DL
22 headache disorder KG + DL
23 trigeminal autonomic cephalalgia KG + DL
24 posteroinferior myocardial infarction KG + DL
25 posterolateral myocardial infarction KG + DL
26 acute pulmonary heart disease KG + DL
27 septal myocardial infarction KG + DL
28 high output heart failure KG + DL
29 idiopathic granulomatous myositis KG + DL
30 myositis fibrosa KG + DL
31 coronary stenosis KG + DL
32 tendinitis KG + DL
33 hepatic porphyria KG + DL
34 symptomatic heart failure KG + DL
35 Jeune syndrome situs inversus KG + DL
36 paratenonitis KG + DL

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search


Copyright © 2026 藥提醒科技有限公司 (yao.care). For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.